Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Lymphoma, Non-Hodgkin 4Lymphoma 4Cardiotoxicity 4Prostatic Neoplasms 3Lung Neoplasms 3Hematologic Neoplasms 3Heart Failure 3Small Cell Lung Carcinoma 2Multiple Myeloma 2Leukemia 2Carcinoma in Situ 2Breast Neoplasms 2Vulvar Neoplasms 1Vulvar Diseases 1Ventricular Dysfunction, Left 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Thoracic Neoplasms 1Stomach Neoplasms 1Sleep Initiation and Maintenance Disorders 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Peritoneal Neoplasms 1Papillomavirus Infections 1Ovarian Neoplasms 1Nose Neoplasms 1Neoplasms 1Myelodysplastic Syndromes 1Metastatic Solid Tumors 1Metabolic Syndrome 1

Interventions

Peripheral Blood Stem Cell Transplantation 32fludarabine phosphate 29Cyclophosphamide 26Whole-Body Irradiation 21Cyclosporine 20Busulfan 20Mycophenolic Acid 19Tacrolimus 16Antilymphocyte Serum 14Methotrexate 13romidepsin 12Etoposide 12Filgrastim 11Melphalan 9Psychiatric Rehabilitation 8Methylprednisolone 8Dexamethasone 8Bexarotene 8Vorinostat 7Flow Cytometry 7Therapeutics 6Radiotherapy 6Calcium Dobesilate 6Brentuximab Vedotin 6Bortezomib 6Alemtuzumab 6sargramostim 5fludarabine 5denileukin diftitox 5Polymerase Chain Reaction 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoma, T-Cell, Cutaneous × Electrocardiography × Clear all
NCT04447027 2026-01-30

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
26 enrolled 24 charts
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡